Literature DB >> 23300338

The Akt DUBbed InAktive.

Kui Lin1.   

Abstract

Akt is a central node in the phosphoinositide-3 kinase-Akt-mammalian target of rapamycin pathway and is activated by a multistep process in response to growth factor stimulation. An additional layer of posttranslational modification has emerged as a new paradigm in the regulation of Akt. The identification of an E3 ligase for Lys(63)-linked ubiquitination of Akt has now been complemented with the discovery of the tumor suppressor cylindromatosis as a deubiquitinating enzyme (DUB) for Akt. Thus, like phosphorylation and dephosphorylation, cycles of ubiquitination and deubiquitination provide additional on-off switches that keep Akt activity in balance, and disturbances in this balance have pathological consequences.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23300338     DOI: 10.1126/scisignal.2003864

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  5 in total

1.  TRAF4 is a critical molecule for Akt activation in lung cancer.

Authors:  Wei Li; Cong Peng; Mee-Hyun Lee; DoYoung Lim; Feng Zhu; Yang Fu; Ge Yang; Yuqiao Sheng; Lanbo Xiao; Xin Dong; WeiYa Ma; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Cancer Res       Date:  2013-10-23       Impact factor: 12.701

2.  Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis.

Authors:  Monica Hellesøy; James B Lorens
Journal:  Mol Biol Cell       Date:  2015-05-28       Impact factor: 4.138

3.  Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

Authors:  Harish Potu; Luke F Peterson; Anupama Pal; Monique Verhaegen; Juxiang Cao; Moshe Talpaz; Nicholas J Donato
Journal:  Oncotarget       Date:  2014-07-30

4.  A novel reporter for real-time, quantitative imaging of AKT-directed K63-poly-ubiquitination in living cells.

Authors:  Shyam Nyati; Nauman Chaudhry; Areeb Chatur; Brandon S Gregg; Lauren Kimmel; Dheeraj Khare; Venkatesha Basrur; Dipankar Ray; Alnawaz Rehemtulla
Journal:  Oncotarget       Date:  2018-01-25

5.  Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination.

Authors:  Chengjiang Qiu; Kairui Liu; Sheng Zhang; Simin Gao; Weirun Chen; Dateng Li; Youxing Huang
Journal:  Drug Des Devel Ther       Date:  2020-03-05       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.